Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on Novo Nordisk’s (NVO) diabetes and weight loss drugs start expiring as soon as next year, The Financial Times’ Hannah Kuchler reports. Patents on the branded versions are due to expire in Canada, China, India and Brazil in 2026, and in other markets between 2028 and 2032, the report notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Morning Movers: Redfin soars and Rocket Companies dips following deal
- Novo Nordisk’s CagriSema Shows Promising Results in Weight Loss Trial
- Novo Nordisk down 6% after results for trial of weight-loss drug CagriSema
- Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
- Hims & Hers Stock (HIMS) Soars on Plans to Shutter Acne Treatment Unit